Webinars to the public are an hour in length and are live-streamed on our YouTube Channel. They will also be recorded and available for later viewing below. Our Cohort receives personalised and closed-door Q&A sessions after each public livestream.
The goal of the MedTech Innovator webinars is to provide the medtech ecosystem and our portfolio companies with feedback from experts and professionals in areas that are specific to the strategic needs outlined in our discussions and surveys. Strategic areas to be covered include: intellectual property, product development, commercialization, reimbursement, healthcare economics, regulatory strategy, clinical trial design and execution, and fundraising.
Our webinars are administered virtually and consist of one or more panelists addressing key questions supplied in advance by the MedTech Innovator Accelerator companies, as well as a general discussion on the topic within the context of the evolving healthcare ecosystem.
Stephen is Director of New Ventures and Transactions at Johnson & Johnson Innovation, Asia Pacific. In this role, he is responsible for the deployment of the APIC strategy in Greater China by identifying opportunities (in Pharmaceuticals, Consumer Healthcare and Medical Device) and building networks within the innovation ecosystem. Stephen has over 20 years of experience in the life science sector. Prior to joining Johnson & Johnson, Stephen was the Managing Director of Kybora EM (formerly Torreya EM) where he was responsible for Asia Pacific business development focusing on licensing and M&A advisory services. Stephen is experienced in bringing together investment opportunities and funding. He has been the founder and CEO of CASiGEN Pharma (a Ventac portfolio company) and BioMatrix Dx. He also served as a partner at Ventac Partners where he played a key role in portfolio company building, strategy, marketing, product analysis and IP development. He has also worked as a consultant for 3V SourceOne Capital, Applied Strategies Consulting, First State Investments, and as a patent examiner for the USPTO. Stephen received his D.Phil. in Biochemistry from the University of Oxford, Merton College. He holds an MBA from the University of Chicago Booth School of Business.
Florian leads Strategy and Business Development in Asia Pacific for Siemens Healthineers as well as Marketing & Sales Enablement, focusing his time on strengthening the Asian footprint for the company. He is seeking for new opportunities and partnerships with innovative companies and institutions across the region. Prior to his Asia Pacific role, he held a number of leadership roles in the areas of Marketing, Customer Services, Business Development and Strategy.
Mark began his financial service careers in PwC Canada and has worked in multiple countries in private client services before he moved to the deal’s advisory services. To date, Mark has participated in multiple acquisitions for both corporate and PE investors of deal sizes up to 4 billion USD. He spent a short period of time in China with a bulge private equity firm, focused in technology sector, before he joined Pureland Venture in 2017. He currently is in charge of the Med-Tech Venture Arm, looking for impact investments that can inject value into patient caring system. Mark earned his BBA from University of Toronto, and obtained his CA, CPA licenses in Canada.
Azran Osman-Rani is currently the founder of Naluri Hidup, a digital health technology company providing a cost-effective, accessible digital solution to provide mental health and wellness support, and help users adopt healthier lifestyle behaviour changes.
Osman-Rani is active in the internet technology space as a co-founder and investor to iflix, MoneyMatch, Cognifyx, and YellowPorter. He was previously CEO of iflix in Malaysia and its Group COO – a disruptive internet television video-on-demand service that was launched in Kuala Lumpur in 2015, and now operates across over 30 markets across Asia, Middle East and Africa with 700 employees less than three years from launch.
Previously Osman-Rani was the founding CEO of AirAsia X, the world’s pioneer low-cost longhaul airline. He led the start-up team that developed the business plan, raised capital, secured relevant licenses, and launched AirAsia X’s first flight in November 2007. AirAsia X since expanded from one aircraft to 26, employing over 2,500 staff, and approximately US$1 billion in annual revenue in 2014. Osman-Rani led the development of AirAsia X’s business model that broke many long-haul airline conventions and pioneered various innovations including the 2013-2014 Skytrax World’s Best Low-Cost Airline Business Class flatbed seats, Quiet Zone, Fly-Thru connections, Seat assignments and upgrade options, and In-flight entertainment services.
Prior to AirAsia X, Azran Osman-Rani was formerly the Senior Director of Business Development for Astro All Asia Networks plc, where he led the start-up and business building of Astro’s media, creative content, and technology investments and joint ventures across Southeast Asia, India and Greater China.
Joseph is the Managing Partner of Verge HealthTech Fund focusing on early stage healthcare technology companies relevant to emerging markets. Prior to this, Joseph was a scientist researching new cancer therapies, a medical device entrepreneur, and a management consultant for Oliver Wyman where he led life sciences and digital health across Asia. He has 19 scientific publications, 3 patents, and has made investments in 20 healthcare technology companies to date. Joseph has a PhD from the University of Toronto, and an MBA from the Richard Ivey School of Business.
Medtech R&D with 25+ years experience in leading R&D organizations, technology and innovation stApzc and Globalrategies with Ip management n strategic partnerships. Passiobatedriver of Digital health technologies and business model innovations. Leadership roles in R&D at JnJ and Boston Scientific across 10+ disease platforms, business units and more than 15+ product launches and 50+ patents delivered by high performance teams. Currently leading J&J Vision APAC R&D and collaboration with Singapore Eye Research Institute.
Yan Lin is an experienced business development professional specializing in the development of medical technologies for both mature markets and developing world applications. She has found success building businesses in the US, Europe and APAC markets.
As the first local hire in the Singapore office, she built Cambridge Consultants’ medtech business in APAC over the course of 5 years. Prior experiences includes developing next generation DNA sequencing technology, molecular diagnostics, and immunoassays.
With her knowledge on regulatory, reimbursement, competitive landscapes, and product development, Yan Lin is a strategic advisor on commercial and product development strategy. Graduated top of her biomedical engineering class from the University of Southern California. Graduated Masters of Bioscience Enterprise from Cambridge University
Santosh is a Senior Principal Engineer at Oliver Healthcare Packaging, Singapore and is responsible for technical services support for customers within the Asia-Pacific region. He has over 18 years of experience in packaging development, quality assurance, packaging
engineering, new packaging development and technical service. Santosh worked at Edwards Lifesciences and Zimmer Biomet as a packaging engineer, focused on higher-end class III device applications. A portion of his career was also in flexible film development, converting and lamination.
Santosh graduated from Michigan State University, with a Masters in Packaging Science, as well as a Bachelors degree in Chemistry and a Diploma in Packaging Technology from Mumbai University. Santosh is a trained auditor for ISO13485.
Jim Warren joined Jabil in 1998 after graduating from the University of Florida with a Finance and Economics degree and continues his education with ASQ as a Black Belt. Jim started as a Manager in Training, as part of the Jabil Emerging Leaders (JEL) Development program. During his time in the JEL program Jim was rotated through cross-functional positions in Operations, Inventory Control, Supply Chain, Planning, Workcell Management, Design, Quality and Business Development in our St. Petersburg, FL Manufacturing site. The JEL program provided Jim experiential learning of our core competencies that serve as the foundation for his ability to create differentiated solutions for his customers. After completing the JEL program Jim transitioned into a Supply Chain Development role in 2005. During that time Jim lived in Malaysia as well as China as he supported Jabil EMS and Jabil Green Point as a Director of Supply Chain. In each of his customer engagements Jim was able to create significant relationships and opportunities in de-risking our customer’s supply chains. In 2015 Jim joined the Jabil Healthcare division as a Business Unit Director and now leads business teams in the US, Mexico, Ireland, Singapore and China. Over the past year Jim’s scope has increased to add additional customers and a larger footprint in Asia. With view to extend his experience in other divisions, Jim is a contributor to Jabil’s website with insightful commentary on how medical and consumer behavior guide our development and design efforts at Jabil.
Colin A. Chong is Vice President and Chief Technology Officer at KECOJO Pte. Ltd., a product development consulting company currently engaged with Univac Precision Engineering Pte Ltd. and EndoMaster Pte. Ltd.
Colin provides technical, strategic, product development, manufacturing and audit expertise to Singapore-based companies. He helps them leverage technologies into transformative and viable devices in the medical and life science industries.
Prior to joining KECOJO, Colin held various positions in his 35-year career in MedTech including a 17-year tenure at Medtronic Diabetes in the USA. He led research, development and manufacturing efforts for implantable and external insulin pumps, continuous glucose monitoring (CGM) hardware, and single-use, sterile disposable products. As Director of Global Technology Development, he strategically led internal, external and international cross functional teams to understand market segmentation, cost & feature sensitivity, and regulatory strategies. This included product teams in Europe, manufacturing operations in Asia, and quality, regulatory, marketing, finance and clinical evaluation teams in the USA.
Colin received his Bachelor’s and Master’s degrees in Mechanical Engineering from The Ohio State University in Columbus, Ohio, U.S.A.
Colin holds 50 US patents and multiple international patents, and is a recipient of the President’s Award for Outstanding Innovation from Medtronic Diabetes.
Connie Tan joined Jabil Singapore in 2008 as a Business Unit Coordinator responsible for consumer product business. After three years she was promoted to Business Unit Manager with responsibility over Jabil’s cloud-based infrastructure customers in Singapore. Connie joined the newly established Jabil Healthcare in 2015 where she has been instrumental in developing customer relationships, winning new businees, managing business transfer and maintaining production. Most recently, Connie’s success has been celebrated by Jabil Healthcare with a promotion to Senior Business Unit Manager responsible for all Jabil Healthcare activity in Singapore. Connie’s extensive knowledge of the Jabil Healthcare’s business model, along with an amazing team she has helped to build, has won over her customers with three consecutive years of best in class awards.
Dr. Senthil Sockalingam is head of IQVIA Biotech in Japan-Asia Pacific as well as chief medical officer (CMO) for IQVIA Asia Pacific based in Singapore. Dr Senthil is a physician by training, acquiring a MBBS degree from the University of Malaya and practising in Malaysia prior to joining the industry.
In his current role, he leads IQVIA’s specialized clinical development services for the Biotech sector across Japan-Asia Pacific. In addition, he is overall responsible for the safety and ethics of IQVIA clinical development projects in the Asia Pacific region. Prior to joining
IQVIA, Dr Senthil led clinical development and medical affairs for several pharmaceutical companies in the region.
Matthew Wagener currently serves as the Vice President of Clinical Operations at Proxima Clinical Research, Inc. Proxima is a contract research organization focused on assisting emerging pharmaceutical and medical device companies in clinical product development. Matt has over 15 years of industry experience working across multiple life science businesses in key areas including clinical operations, business operations, and business development.
Prior to joining the Proxima team, he was a member of the executive team and the Sr. Director of Corporate Operations at MedSource, a CRO focused on Oncology, Neurology, and Rare Diseases. While at MedSource, Matt successfully managed corporate operations and business development through high growth period (57% CAGR over five years) building operations to support growth. Prior to MedSource, he held several management positions at McKesson Specialty Health / US Oncology. At US Oncology Matt led clinical and business operations for the launch of their oncology CRO through start-up, full service clinical trial operations, and business acquisition. Prior to managing the CRO business unit at US Oncology, he led clinical development for the Lung, GI, Hematology, and Radiation Oncology research programs. He also held other research positions at the University of Texas Medical Branch in Galveston in the department of Orthopedic Surgery and MD Anderson Cancer Center in the department of Radiation Oncology.
Matt received his degree in biomedical science from Texas A&M University. Since starting his career in research, he has worked in key sections of basic and clinical research from bench to bedside to management.
Mary McNamara-Cullinane is Senior Vice President, Regulatory Affairs at Alira Health based in Boston. She has over 25 years of regulatory experience in the medical device, diagnostics and biotech industries. She has successfully authored over 170 510(k)s, multiple PMAs, two De Novo submissions and has been responsible for several clinical trials. In addition, she has strong knowledge of global regulatory practices and registrations in Europe, Korea, and Australia having worked on many technical files and CERs. Most recently, Mary was responsible for US regulatory strategy at Intrinsic Therapeutics, VP of Regulatory and Clinical Affairs at Echo Therapeutics, Director of Regulatory Affairs at Z-Medica, and Director of Regulatory Affairs and Quality Assurance at Molecular Biometrics. Prior to Molecular Biometrics, Mary was in regulatory consulting for 17 years at Medical Device Consultants, Inc.
Over 25 years of Regulatory, Quality, Clinical Trial and Pharmacovigilance experience in Asia with good knowledge in the field of Nutritional, Pharmaceuticals, Medical Devices, Consumer Healthcare and Biological products.
Externally, playing a leading role among all the Regional Regulatory professionals in AHWP (Asian Harmonization Working Party). Developed the First Asia Regulatory Affairs Certificate course since 2007 with over 3800 students in industry, government and universities. Being the founder of ARPA (Asia Regulatory Professionals Associations) since 2010 with over 4800 members. Wrote the first Asia Regulatory Book, Handbook of Medical Device Regulatory Affairs in Asia, 2nd edition now.
Adjunct Lectureship & Visiting Professorship with Nanyang Technological University (Singapore), Tohoku University (Japan), Beijing University (China), Chinese University of Hong Kong (Hong Kong), University of Hong Kong (Hong Kong), Taipei Technical University (Taiwan), University of Sydney (Australia), Dongguk University (Korea)
Chris Hardesty is currently Director, Healthcare and Life Sciences Practice at KPMG in Singapore. Chris has 12 years of experiences in the healthcare industry in key areas such as vendor management solutions as well as research and mentorship to drive innovation activities across the healthcare ecosystem.
In his current role, Chris focuses on on public-private partnerships for patient centricity, market expansion, sustainable financing, novel technology adoption, innovation acceleration, and operational excellence programs.
Chris has a PhD in Public Health Policy from UNC Gillings School of Global Public Health.
Stephanie is currently Director, APAC Health Economics & Market Access, Cardiovascular & Specialty Solutions at Johnson & Johnson in Singapore. Stephanie was previously a Business Model Innovation Analyst at Medtronic International where she designed, planned, and executed market development programs with cardiovascular BUs to improve patient access to care. She was also responsible for building business model innovation capabilities in emerging markets, with coverage spanning Malaysia, Indonesia, Vietnam, Thailand, the Philippines, and India.
Stephanie was also previously a JSPS Postdoctoral Fellow at the University of Tokyo.
Stephanie has a PhD in Materials Science and Engineering from Cornell University.
Leslie Wise is CEO and Managing Director at Evidencematters. Evidencematters makes a wide range of diversified products, for government, corporations, and consumers.
Leslie also serves as Board Member at Orthocell, TryCycle Data Systems, and Sonavi Labs. Prior to this, Leslie was Vice President, Global Healthcare Economics, Market Access and Health Policy where she was responsible for US and OUS reimbursement, health economics and market access for multinational corporation.
Shriekanth Iyer is Strategy & Business Development Director, Connected Health at Irdeto in the Netherlands. In his current role, he is responsible for driving new opportunities with partnerships and collaboration to co-create solutions to solve the product and data security challenges.
Prior to pursuing his MBA at IMD Business School in Switzerland, Shriekanth has served as Strategy Consultant, Digital Health at Medows Sàrl where he conducted strategic assessment and validated hypothesis of different healthcare market-specific datasets & insights to drive commercial effectiveness for MedTech and Digital Health clients in Europe.
He was also previously ASEAN Healthcare Digital Business Leader at GE Healthcare where he led consultative solution sales, business development, and channel development in South East Asian markets or the ASEAN region..
Dr. Adam CHEE is a Convergence Scientist familiar with Health(& Care), Informatics, Innovation, Technologies and (equally important,) the Business aspects of the ecosystem. Serving as a coach & conduit between various key opinion leaders & stakeholders, engaging at operational, strategic and governmental levels as well as developing commercial relationships with global firms and local start-ups in the utilization of Health Informatics and Digital Health as an enabler in addressing the challenges of new and existing models of health(care).
Adam brings more than 20 years of health informatics, digital health, innovation, technologies and business experience. Prior to joining NUS, he spearheaded many significant and notable projects across Asia Pacific and Middle East through the provision of digital health transformation expertise to both health(care) and solution providers via consulting assignments, executive coaching, training, leadership and speaking engagements.
Rahul Gupta is the Global Business Manager for Cybersecurity at UL and leads cybersecurity testing and certification services related to Industry 4.0 Operation Technologies(OT), Medical, and Automotive. He has 30+ years of experience in consulting, advisory, testing and certification. He has pioneered new digital transformation technologies, connecting Cybersecurity and IoT in Industry 4.0 across multiple critical infrastructure industrial and healthcare sectors. He is an expert in Industrial Automation and Control, IEC 61511 certified in Functional Safety, and an IEC 62443 specialist in ICS/OT Cybersecurity. He has actively participated in the development of standards, presented papers on the subject, and contributed to government/regulatory groups/Standards Committee.
In his current role at UL, he is responsible for establishing the Cyber Security operational business strategy and framework, developing technology partnerships, program-managed new growth initiatives and go-to-market strategies, Owned P&L, and led global Cyber Security Subject matter experts (SMEs), Project Managers and operational teams. Drove Industry 4.0 Cyber Security decisions, participating in industry forums, business councils and conferences.
He is responsible for driving Industry 4.0 cybersecurity business growth in Industrial OT, IIoT, Medical, IoT and Automotive Cyber testing labs at Northbrook -USA, Frankfurt-Germany, Mumbai- India, and Leiden-Netherlands.
Before joining UL, Rahul led sales and commercial business development strategy in HONEYWELL International, identifying new business opportunities and developing the Pharma Life sciences industry vertical.
He is familiar with applicable cyber security standards for healthcare/medical devices such as UL-2900, US FDA, IMDRF and other countries guidance on Medical device Cybersecurity.
Sanjay is a healthcare leader with over 30 years of experience in senior leadership roles and has worked with the CEOs of Fortune 500 companies. Sanjay is based in Singapore and is a Harvard Business School alumnus.
In his last assignment, he was the President, Asia Pacific for Hologic Inc a leader in women’s health. He has previously served as the President-Asia Pacific for Baxter International Inc. with responsibility of over 12,000 employees and $2 Billion revenue in Asia Pacific. Before that, Sanjay spent 10 years at Boston Scientific Corporation. Sanjay has lived and worked in London, India, China, and Singapore.
He has been an invited speaker for several years at INSEAD/ NUS Business School in Singapore and CEIBS Shanghai. Sanjay is a graduate of the Advanced Management Programme (AMP 179) of Harvard Business School. Sanjay has served on the board of APACMED for several years and has been a founding member of the board of Advamed in China.
His lifetime career goal is to create 10,000 employment opportunities and at the end of 30 years in the healthcare industry he has been able to create 6,041 new jobs and believes through mentoring the next generation will achieve this milestone even faster. With this goal, he has co-founded the Asia Mentors Circle to accelerating healthcare leadership talent in Asia and make a meaningful difference.
Sanjay has been married to Neetha a life and career coach for over 23 years and is the proud father of two college undergrads Tanya and Neha and a Golden Retriever named Melody.
Shikharesh Das has over three decades of Med Tech sales and marketing experience with deep understanding of clinical workflows in and out of hospital. His expertise lies in working with limited resources and finding the optimum pathway to help Start-ups expand in new markets. At Ontogenix, Shikharesh is responsible for actionable adoption strategies for new products in international markets for Medtech and Digital Health Products. In his previous life, Shikharesh held leadership positions with GE Healthcare and with Philips Medical Systems.
Shikharesh obtained his MBA degree from the National University of Singapore and is well known in speaker circles for market entry strategies. He has formally mentored more than 25 MedTech startups for commercialization.
An extremely experienced digital health expert, Ken Nelson is currently the Head of Digital Health, Diagnostics & Monitoring at Biotronik.
With 20 years of experience in digital health, medical device, and remote patient monitoring, Ken has held senior leadership experience ranging from a Fortune 500 company (Boston Scientific) to 3 start-ups, 1 of which eventually led to an extremely successful IPO (iRhythm) and another which is well on its way to doing the same (Bardy Diagnostics).
Some of his notable successful accomplishments include leading Biotelemetry to profitability for the first time ever, and growing them to be the the number one market share player by developing a winning team and culture to successfully growing revenue for 18 consecutive quarters from $111M in revenue in 2012 to $208M in revenue in 2016, exceeding quota in all 18 quarters.
|JUL 14||1 – Perfecting Your Pitch Video|
|JUL 21||2 – Strategic Partnerships & Working with Multinationals|
|JUL 28||3 – Fund Raising & Deal Structuring|
|AUG 4||4 – Product Design & Development|
|AUG 12||5 – Manufacturing & Supply Chain Management: Avoiding Pitfalls|
|AUG 18||6 – Clinical Trial Management & Working with CROs|
|AUG 25||7 – Regulatory Pathways: US versus APAC|
|SEPT 1||8 – Health Economics & Working with Payers: US versus APAC|
|SEPT 8||9 – Cybersecurity & Data Privacy|
|SEPT 15||10 – Commercialization: Managing KOL Networks, Sales & Distribution|
|OCT 19 – 20||2021 APAC GRAND FINALS|